Radioimmunotherapy as a Therapeutic Option for Non-Hodgkin's Lymphoma

Seminars in Radiation Oncology

Volumn 17, Issue 3, 2007, Pages 176-183

  Macklis, Roger M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; ISOTOPE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DOSIMETRY; DRUG CLEARANCE; DRUG HALF LIFE; HEMATOLOGIC DISEASE; HUMAN; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION SAFETY; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 34250758914     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.02.003     Document Type: Article

References (47)

1. Pohlman B.L., Sweetenham J.W., and Macklis R.M. Review of clinical radioimmunotherapy. Expert Rev Anticancer Ther 22 (2006) 445-462
2. Davies A.J., Rohatiner A.Z., Howell S., et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 22 (2004) 1469-1479
3. Macklis R.M. Radithor and the era of mild radium therapy. JAMA 264 (1990) 614-618
4. Press O.W. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 30 suppl 4 (2003) 10-21
5. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 2453-2463
6. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
7. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329 (1993) 459-465
8. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3793-3803
9. Leichner P.K., Yang N.C., Frenkel T.L., et al. Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma. Int J Radiat Oncol Biol Phys 14 (1988) 1033-1042
10. Mach J.P., Buchegger F., and Pelegrin A. Progress in Radiolabeled Monoclonal Antibodies for Cancer Diagnosis and Potential for Therapy (1989), Lippincott, Philadelphia
11. Dillehay L.E. A model of cell killing by low-dose-rate radiation including repair of sublethal damage, G2 block, and cell division. Radiat Res 124 (1990) 201-207
12. Yorke E.D., Wessels B.W., and Bradley E.W. Absorbed dose averages and dose heterogeneities in radioummunotherapy. Antibody Immunoconjugates Radiopharm 4 (1991) 623-626
13. Witzig T.E., Vukov A.M., Habermann T.M., et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 1103-1108
14. Hernandez M.C., and Knox S.J. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 59 (2004) 1274-1287
15. Macklis R.M. How and why does radioimmunotherapy work?. Int J Radiat Oncol Biol Phys 59 (2004) 1269-1271
16. DeNardo S.J. Radioimmunodetection and therapy of breast cancer. Semin Nucl Med 35 (2005) 143-151
17. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14 (1996) 1974-1981
18. Knox S.J., Goris M.L., Trisler K., et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2 (1996) 457-470
19. Koral K.F., Kaminski M.S., and Wahl R.L. Correlation of tumor radiation-absorbed dose with response is easier to find in previously untreated patients. J Nucl Med 44 (2003) 1541-1543 author reply 1543
20. Wiseman G.A., Kornmehl E., Leigh B., et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med 44 (2003) 465-474
21. Gokhale A.S., Mayadev J., Pohlman B., et al. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 194-201
22. Du Y., Honeychurch J., Cragg M.S., et al. Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 103 (2004) 1485-1494
23. Kaminski M.S., Zelenetz A.D., Press O.W., et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19 (2001) 3918-3928
24. Gordon L.I., Molina A., Witzig T., et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 103 (2004) 4429-4431
25. Kassis A.I., and Adelstein S.J. Radiobiologic principles in radionuclide therapy. J Nucl Med 46 suppl 1 (2005) 4S-12S
26. O'Keefe T.L., Williams G.T., Davies S.L., et al. Mice carrying a CD20 gene disruption. Immunogenetics 48 (1998) 125-132
27. Shan D., Ledbetter J.A., and Press O.W. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48 (2000) 673-683
28. Hofmeister J.K., Cooney D., and Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 26 (2000) 133-143
29. Li H., Ayer L.M., Lytton J., et al. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 278 (2003) 42427-42434
30. Bellosillo B., Villamor N., Lopez-Guillermo A., et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 98 (2001) 2771-2777
31. Hainsworth J.D., Litchy S., Burris III H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 20 (2002) 4261-4267
32. Czuczman M.S., Weaver R., Alkuzweny B., et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22 (2004) 4711-4716
33. Witzig T.E., White C.A., Gordon L.I., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 21 (2003) 1263-1270
34. Horning S.J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23 (2005) 712-719
35. Gregory S.A., Leonard J.P., and Knox S.J. The iodine 131I tositumomab therapeutic regimen: summary of safety in 995 patients with relapsed/refractory low-grade (LG) and transformed LG non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 22 (2004) 6732 abstract
36. 90Y) Ibritumomab tiuxetan (Zevalin) therapy with rituximab maintenance in patients wtih untreated low-grade follicular lymphoma. Blood 104 (2004) 720 abstract
37. Bennett J.M., Kaminski M.S., Leonard J.P., et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105 (2005) 4576-4582
38. Vose J.M., Wahl R.L., Saleh M., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18 (2000) 1316-1323
39. Wiseman G.A., Gordon L.I., Multani P.S., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99 (2002) 4336-4342
40. Cheson B.D. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs 19 (2005) 309-322
41. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
42. Pfreundschuh M., Truemper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7 (2006) 379-391
43. Kahl B.S. Treatment of indolent lymphomas in the era of targeted therapy. Clin Adv Hematol Oncol 4 (2006) 6-7
44. Nademanee A., Forman S., Molina A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2005) 2896-2902
45. Vose J.M., Bierman P.J., Enke C., et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 461-467
46. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (2005) 496-498
47. Press O.W., Eary J.F., Gooley T., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96 (2000) 2934-2942